MedTrace Logo

Dexcom G6 Continuous Glucose Monitoring in Hemodialysis

NCT04217161 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-06-12

No results posted yet for this study

Summary

This is a pilot study enrolling adult hemodialysis patients with diabetes recruited from the University of California Irvine Medical Center (UCIMC) who will undergo simultaneous measurement of glucose levels using 1) continuous glucose monitor (CGM) measured by a Dexcom G6 device vs. 2) "gold-standard" blood glucose levels using capillary fingerstick or venous blood glucose measurements obtained on a point of care (POC) blood glucose meter. The study will assess Dexcom G6 accuracy by comparing glucose levels on the CGM device vs. blood glucose measurements in the study population.

Conditions

  • Diabetes
  • Hemodialysis
  • Glucose Measurement

Interventions

DEVICE

Dexcom G6 Continuous Glucose Monitor

Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement

Sponsors & Collaborators

  • DexCom, Inc.

    collaborator INDUSTRY

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Connie Rhee, MD, MSc · Faculty

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2023-12-21
Completion
2023-12-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04217161 on ClinicalTrials.gov